{"id":"https://openalex.org/W2610165232","doi":"https://doi.org/10.1634/theoncologist.2017-0137","title":"Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors","display_name":"Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors","publication_year":2017,"publication_date":"2017-05-02","ids":{"openalex":"https://openalex.org/W2610165232","doi":"https://doi.org/10.1634/theoncologist.2017-0137","mag":"2610165232","pmid":"https://pubmed.ncbi.nlm.nih.gov/28465370","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5469595"},"language":"en","primary_location":{"id":"doi:10.1634/theoncologist.2017-0137","doi":"https://doi.org/10.1634/theoncologist.2017-0137","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2017-0137","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5469595","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076296804","display_name":"Junning Cao","orcid":"https://orcid.org/0000-0002-3146-9413","observed_orcids":["https://orcid.org/0000-0002-3146-9413"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Junning Cao","raw_affiliation_strings":["Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070113542","display_name":"Dongmei Ji","orcid":"https://orcid.org/0000-0003-0647-0153","observed_orcids":["https://orcid.org/0000-0003-0647-0153"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Dongmei Ji","raw_affiliation_strings":["Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115588715","display_name":"Zhiyu Chen","orcid":"https://orcid.org/0009-0003-4316-0952","observed_orcids":["https://orcid.org/0009-0003-4316-0952"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhiyu Chen","raw_affiliation_strings":["Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037468161","display_name":"Weina Shen","orcid":"https://orcid.org/0000-0002-6978-8866","observed_orcids":["https://orcid.org/0000-0002-6978-8866"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Weina Shen","raw_affiliation_strings":["Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100346155","display_name":"Jin Wang","orcid":"https://orcid.org/0000-0002-3928-7032","observed_orcids":["https://orcid.org/0000-0002-3928-7032"]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jin Wang","raw_affiliation_strings":["Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015037933","display_name":"Baoyue Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Baoyue Li","raw_affiliation_strings":["Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113831304","display_name":"Haidong Chi","orcid":"https://orcid.org/0009-0006-2795-5255","observed_orcids":["https://orcid.org/0009-0006-2795-5255"]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Haidong Chi","raw_affiliation_strings":["Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly China Drug Development and Medical Affairs Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055671933","display_name":"Amanda J. Long","orcid":"https://orcid.org/0009-0005-7307-3934","observed_orcids":["https://orcid.org/0009-0005-7307-3934"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda Long","raw_affiliation_strings":["Global Pharmacokinetics/Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Pharmacokinetics/Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101483571","display_name":"Ling Gao","orcid":"https://orcid.org/0000-0002-0091-2937","observed_orcids":["https://orcid.org/0000-0002-0091-2937"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Gao","raw_affiliation_strings":["Global Pharmacokinetics/Pharmacodynamics, Eli Lilly and Company, Bridgewater, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Pharmacokinetics/Pharmacodynamics, Eli Lilly and Company, Bridgewater, Massachusetts, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100364751","display_name":"Jin Li","orcid":"https://orcid.org/0000-0001-5523-0055","observed_orcids":["https://orcid.org/0000-0001-5523-0055"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Jin Li","raw_affiliation_strings":["Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China","institution_ids":["https://openalex.org/I4210093194"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5100364751"],"corresponding_institution_ids":["https://openalex.org/I4210093194"],"apc_list":{"value":3852,"currency":"USD","value_usd":3852},"apc_paid":null,"fwci":0.2923,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.50797059,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"22","issue":"6","first_page":"638","last_page":"e56"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.5429999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.5429999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.24770000576972961,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.047200001776218414,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9409999847412109},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8859999775886536},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9070000052452087},{"id":"https://openalex.org/keywords/chinese-patients","display_name":"Chinese patients","score":0.5479999780654907},{"id":"https://openalex.org/keywords/vegfr-2-inhibitors","display_name":"VEGFR-2 inhibitors","score":0.7239999771118164},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8100000023841858},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.871999979019165}],"concepts":[{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.9779988527297974},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8961998224258423},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7474109530448914},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7056174278259277},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6628503799438477},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.558805525302887},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5110577344894409},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.496961385011673},{"id":"https://openalex.org/C162156334","wikidata":"https://www.wikidata.org/wiki/Q473420","display_name":"Dose","level":2,"score":0.43956291675567627},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.41394490003585815},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3805404305458069},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36597543954849243},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36449986696243286},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3644202947616577},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.32613393664360046},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.10825732350349426},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.10502132773399353}],"mesh":[{"descriptor_ui":"D000096662","descriptor_name":"Ramucirumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002681","descriptor_name":"China","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1634/theoncologist.2017-0137","doi":"https://doi.org/10.1634/theoncologist.2017-0137","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2017-0137","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5469595","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5469595","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},{"id":"pmid:28465370","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28465370","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The oncologist","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:5469595","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5469595","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1867019634","https://openalex.org/W1967841898","https://openalex.org/W1971837077","https://openalex.org/W1972053328","https://openalex.org/W1994193851","https://openalex.org/W2069361214","https://openalex.org/W2104759721","https://openalex.org/W2111237964","https://openalex.org/W2121847974","https://openalex.org/W2125913015","https://openalex.org/W2140980839","https://openalex.org/W2151053740","https://openalex.org/W2153297361","https://openalex.org/W2472000057","https://openalex.org/W2513941050","https://openalex.org/W4324262440"],"related_works":["https://openalex.org/W2497067009","https://openalex.org/W2585319073","https://openalex.org/W2125913015","https://openalex.org/W2105727919","https://openalex.org/W4220780195","https://openalex.org/W3094017079","https://openalex.org/W4237847047","https://openalex.org/W2513941050","https://openalex.org/W2384032057","https://openalex.org/W1488260411"],"abstract_inverted_index":{"Abstract":[0],"Lessons":[1],"Learned":[2],"Ramucirumab":[3,108,238],"was":[4,35,59,88,93,109,162,177,209],"well":[5,242],"tolerated":[6,160,243],"in":[7,19,24,31,71,101,201,205,244,253,260],"Chinese":[8,25,72,202,245,254],"patients":[9,26,73,148,165,246,255],"with":[10,74,99,225,247],"advanced":[11,75,248],"solid":[12,76,249],"tumors,":[13],"and":[14,44,66,104,126,139,198,217],"adverse":[15,171,175],"events":[16],"were":[17,27,79,142,256],"manageable":[18],"this":[20],"study.":[21],"Pharmacokinetics":[22],"characteristics":[23,252],"similar":[28,257],"to":[29,61,81,156,240,258],"those":[30,259],"other":[32,206,261],"populations.":[33,207,262],"Immunogenicity":[34,208],"not":[36,210],"detected.":[37,211],"No":[38,158,212],"efficacy":[39],"conclusion":[40],"could":[41],"be":[42,241],"drawn,":[43],"further":[45],"randomized":[46],"studies":[47],"are":[48],"warranted.":[49],"Background":[50],"This":[51],"single-arm,":[52],"nonrandomized,":[53],"open-label,":[54],"dose-escalation,":[55],"phase":[56],"I":[57],"study":[58],"designed":[60],"evaluate":[62],"the":[63],"safety,":[64],"tolerability,":[65],"pharmacokinetics":[67],"(PK)":[68],"of":[69,184,196,229],"ramucirumab":[70,190],"tumors":[77],"that":[78,189],"resistant":[80],"standard":[82,86],"therapy":[83,87],"or":[84],"no":[85],"available.":[89],"Methods":[90],"Dose":[91],"escalation":[92],"a":[94,226],"3":[95,97,105,124],"+":[96],"design,":[98],"expansion":[100],"Cohorts":[102],"2":[103,119,130,150],"for":[106,179],"PK.":[107],"given":[110],"intravenously":[111],"at":[112,167],"three":[113],"different":[114],"dosages:":[115],"6":[116],"mg/kg":[117,122,128],"every":[118,123,129],"weeks,":[120,125],"10":[121],"8":[127],"weeks.":[131],"Safety":[132],"analyses":[133,187],"included":[134],"all":[135],"patients.":[136,185],"PK,":[137],"immunogenicity,":[138],"antitumor":[140],"activity":[141],"also":[143],"assessed.":[144],"Results":[145],"Among":[146],"28":[147],"treated,":[149],"experienced":[151,166],"dose-limiting":[152],"toxicity,":[153],"possibly":[154],"related":[155],"ramucirumab.":[157],"maximum":[159],"dose":[161],"determined.":[163],"All":[164],"least":[168],"one":[169],"treatment-emergent":[170],"event.":[172],"Grade":[173],"\u22653":[174],"event":[176],"reported":[178],"53.6%":[180],"(n":[181,219],"=":[182,220],"15)":[183],"PK":[186,251],"indicated":[188],"had":[191,214,222],"low":[192],"clearance,":[193],"small":[194],"volume":[195],"distribution,":[197],"long":[199],"half-life":[200],"patients,":[203],"as":[204],"patient":[213],"complete/partial":[215],"response,":[216],"64.3%":[218],"18)":[221],"stable":[223],"disease":[224],"median":[227],"duration":[228],"5.55":[230],"months":[231],"(95%":[232],"confidence":[233],"interval:":[234],"3.38\u22127.13":[235],"months).":[236],"Conclusion":[237],"appeared":[239],"tumors.":[250]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-05-12T00:00:00"}